Login to Your Account



Eye Kidney Not: Lux Phase III Fizzles, Isotechnika to Refocus

By Randy Osborne
Staff Writer

Thursday, December 27, 2012
in_the_clinic.jpg

Now that licensing partner Lux Biosciences Inc. has lifted the lid on short-of-the-mark Phase III results from another try with voclosporin for uveitis, Isotechnika Pharma Inc. is turning its attention fully to nephrology – especially kidney transplants, the indication for which the calcineurin inhibitor originally was designed.

"We just need to stick to our knitting," said Robert Foster, founder of Isotechnika, who has been an officer and director at the Edmonton, Alberta-based firm since 1993.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription